Efficacy and safety of an all-oral delamanid-containing regimen in the treatment of multidrug-resistant pulmonary tuberculosis complicated by extrapulmonary tuberculosis: Four case reports and review of the literature

In this small case series of patients with MDR-TB and diverse extrapulmonary manifestations, an all-oral DLM-containing regimen was associated with significant lesion regression and demonstrated a manageable safety profile. QT prolongation was the primary adverse event, reversible with intervention. These findings-representing China's first systematic report of this regimen for multisite EPTB, including the pediatric case-align with WHO guidance and suggest DLM's potential utility based on its extensive tissue penetration. Further validation in larger multicenter studies is warranted.